What are the limitations of the ipi dlbcl?

While the ipi dlbcl is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the ipi dlbcl to ensure safe bedside use and optimal diagnostic accuracy.

How does the ipi dlbcl compare to other Hematology scores?

The ipi dlbcl is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the ipi dlbcl free to use?

Yes. OpiCalc provides the ipi dlbcl completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

935 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

IPI (International Prognostic Index)

IPI (International Prognostic Index): The standard clinical tool for DLBCL. One point for each adverse factor.

Total IPI Score

0

Risk Group

Low

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostic stratification of patients with aggressive Non-Hodgkin Lymphoma (NHL), specifically Diffuse Large B-cell Lymphoma (DLBCL).

To guide intensity of therapy and clinical trial stratification.

Initial baseline assessment of overall survival (OS) risk.

Patient Population

Adult patients with aggressive NHL. Derived before the rituximab era but remains a foundational reference.

When Not to Rely on This Score Alone

Follicular Lymphoma — use FLIPI instead.

Rituximab era — consider R-IPI or NCCN-IPI for more accurate prediction in patients receiving modern immunochemotherapy.

Age ≤ 60 — consider the Age-Adjusted IPI (aaIPI).

Section 2

Formula & Logic

Scoring Variables (+1 point each)

Age > 60 years

Serum LDH > Upper Limit of Normal

ECOG Performance Status ≥ 2

Ann Arbor Stage III or IV

Extranodal Sites > 1

Risk Groups

Score	Risk Group	Estimated 5-y OS (Original)
0 - 1	Low	73%
2	Low-Intermediate	51%
3	High-Intermediate	43%
4 - 5	High	26%

Section 3

Pearls/Pitfalls

Molecular vs. Clinical

While IPI is purely clinical, modern lymphoma management also integrates cell-of-origin (COO) and double-hit (MYC/BCL2) status. However, IPI remains the most widely cited clinical score worldwide.

Section 4

Evidence Appraisal

Primary Score

A predictive model for aggressive non-Hodgkin's lymphoma.

Shipp MA et al. • New England Journal of Medicine. 1993;329(14):987-94.

View Source

Section 5

Literature

Development

Developed by an international consortium to provide a reliable, easily applicable clinical tool for trial design in the pre-molecular era of hematology.

Last Comprehensive Review: 2026

Related Hematology Tools

WHO 2022 AML Classification Mapper

ELN 2022 AML Risk Classification

JAK2V617F Allele Burden Interpreter

Sokal/EUTOS/ELTS Comparison

Have feedback about this calculator?Let us know.